In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ViroPharma's Second Act: First a Tough One to Follow

Executive Summary

In the year since biotech ViroPharma acquired Vancocin, it's transformed itself from a development-style biotech into an earnings-driven success. One result: a new shareholder base that likes regular profit increases and may not tolerate the lower margins that come with additional R&D spending or in-licensing costs. But with generics and other competitors on the near-term horizon, ViroPharma needs a dramatic second-act solution.

Related Content

Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant
Aton Pharma Moves Beyond Its Merck Connections With Pick-up From Bristol
Two Steps Back: Ligand Ditches Commercial Assets
Two Steps Back: Ligand Ditches Commercial Assets
Cephalon: Can Spec Pharma do R&D?
Cephalon: Can Spec Pharma do R&D?
The New Out-Licensing Start-Ups: Securing Product Supply
Biotechs Brace to Battle a Deadly GI Bacterium
Enzon: The Perils of Profitability


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts